Neurologic disorder in a 65-year-old man after treatment of colon cancer

New England Journal of Medicine

Volumn 341, Issue 7, 1999, Pages 512-519

  Recht, L D ^a   Primavera, J M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CLARITHROMYCIN; FLUOROURACIL; GLIBENCLAMIDE; LEVAMISOLE; SIMVASTATIN;

AGED; ARTICLE; CASE REPORT; COGNITIVE DEFECT; COLON CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DEMYELINATING DISEASE; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; GAIT DISORDER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOENCEPHALOPATHY; MALE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0033549820     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199908123410708     Document Type: Article

References (43)

1. Posner JB. Neurologic complications of cancer. Philadelphia: F.A. Davis, 1995.
2. Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol 1988;45:741-4.
3. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998;82:733-9.
4. Chaturvedi S, Ansell J, Recht LD. Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability? Stroke 1994;25:1215-8.
5. Rogers LR, Cho ES, Kempin S, Posner JB. Cerebral infarction from non-bacterial thrombotic endocarditis: clinical and pathological study including the effects of anticoagulation. Am J Med 1987;83:746-56.
6. Walker DL. Progressive multifocal leukoencephalopathy. In: Vinken PJ, Bruyn GW, Klawans HL, Koetsier JC, eds. Demyelinating diseases. Vol. 47 of Handbook of clinical neurology. Rev. series 3. Amsterdam: Elsevier, 1985:503-24.
7. Laune JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large bowl carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989;7:1447-56.
8. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
9. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6:1653-64.
10. Aoki N. Reversible leukoencephalopathy caused by 5-fluorouracil derivatives, presenting as akinetic mutism. Surg Neurol 1986;25:279-82.
11. Greenwald ES. Organic mental changes with fluorouracil therapy. JAMA 1976;235:248-9.
12. Lynch HT, Groszcz CP, Albano WA, Lynch JF. "Organic brain syndrome" secondary to 5-fluorouracil toxicity. Dis Colon Rectum 1981;24: 130-1.
13. Riehl J-L, Brown WJ. Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology 1964;14:961-7.
14. Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents. N Engl J Med 1974;291:75-81.
15. Stevenson HC, Green I, Hamilton JM, Calabro BA, Parkinson DR. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol 1991;9:2052-66.
16. Hirshaut Y, Kesselheim H, Pinsky CM, Braun D Jr, Wanebo HJ, Oettgen HF. Levamisole as an immunoadjuvant: a phase I study and application in breast cancer. Cancer Treat Rep 1978;62:1693-701.
17. Parkinson DR, Cano PO, Jerry LM, et al. Complications of cancer immunotherapy with levamisole. Lancet 1977;1:1129-32.
18. Symoens J, Veys E, Mielants M, Finals R. Adverse reactions to levamisole. Cancer Treat Rep 1978;62:1721-30.
19. Vandevelde M, Boring JG, Hoff EJ, Gingerich DA. The effect of levamisole on the canine central nervous system. J Neuropathol Exp Neurol 1978;37:165-73.
20. Chen TC, Hinton DR, Leichman L, Atkinson RD, Apuzzo ML, Couldwell WT. Multifocal inflammatory leukoencephalopathy associated with levamisole and 5-fluorouracil: case report. Neurosurgery 1994;35: 1138-43.
21. Fassas AB, Gattani AM, Morgello S. Cerebral demyelination with 5-fluorouracil and levamisole. Cancer Invest 1994;12:379-83.
22. Galassi G, Tassone G, Sintini M, Spagnoli M, Bertolani L, Mavilla L. 5-Fluorouracil-and levamisole-associated multifocal leukoencephalopathy. Eur Neurol 1996;36:244-6.
23. Hook CC, Kimmel DW, Kvols LK, et al. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992; 31:262-7.
24. Kimmel DW, Schutt AJ. Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy. Mayo Clin Proc 1993;68:363-5.
25. Leichman L, Brown T, Poplin B. Symptomatic, radiologic and pathologic changes in the central nervous system (CNS) associated with 5-fluorouracil (5-FU) and levamisole (LEV). Proc Am Soc Clin Oncol 1993;12: 198. abstract.
26. Neu IS. Multifocal inflammatory leukoencephalopathy caused by adjuvant therapy with 5-fluorouracil and levamisole after resection for an adenocarcinoma of the colon. Acta Neurol Scand 1993;87:70. [Erratum, Acta Neurol Scand 1993;88:239.]
27. Savarese DM, Gordon J, Smith TW, et al. Cerebral demyclination syndrome in a patient treated with 5-fluorouracil and levamisole: the use of thallium SPECT imaging to assist in noninvasive diagnosis - a case report. Cancer 1996;77:387-94.
28. Lucchinetti CF, Kimmel DW, Pavelko K, Rodriguez M. 5-Fluorouracil and levamisole exacerbate demyelination in susceptible mice infected with Theiler's virus. Exp Neurol 1997;147:123-9.
29. Mertin J, Knight SC, Rudge P, Thompson EJ, Healy MJ. Double-blind, controlled trial of immunosuppression in treatment of multiple sclerosis. Lancet 1980;2:949-51.
30. Hamilton JM, Freedman MA. 5-FU/levamisole update. Princ Pract Oncol Updates 1994;8:1-8.
31. Kimmel DW, Wijdicks EF, Rodriguez M. Multifocal leukoencephalopathy associated with levamisole therapy. Neurology 1995;45:374-6.
32. Lucia P, Pocek M, Passacantando A, Sebastiani ML, Dc Martinis C. Multifocal leukoencephalopathy induced by levamisole. Lancet 1996;348:1450.
33. Connolly KM, Diasio RB, Armstrong RD, Kaplan AM. Decreased immunosuppression associated with antitumor activity of 5-deoxy-5-fluoro-uridine compared to 5-fluorouracil and 5-fluorouridine. Cancer Res 1983; 43:2529-35.
34. MacFarlane DG, Bacon PA. Levamisole-induced vasculitis due to circulating immune complexes. BMJ 1978;1:407-8.
35. Ancri D, Bassett JY. Diagnosis of cerebral metastases by thallium-201. Br J Radiol 1980;53:443-53.
36. Tonami N, Hisada K. Clinical experience of tumor imaging with 201Tl-chloride. Clin Nucl Med 1977;2:75-81.
37. Luppi G, Zoboli A, Barbieri F, Crisi G, Piccini L, Silingardi V. Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer: a report of two cases and review of the literature. Ann Oncol 1996;7:412-5.
38. Figueredo AT, Fawcet SE, Molloy DW, Dobranowski J, Paulseth JE. Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. Cancer Invest 1995;13:608-11.
39. Okeda R, Karakama T, Kimura S, Toizumi S, Mitsushima T, Yokoyama Y. Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs. Acta Neuropathol (Berl) 1984;63: 334-43.
40. Okeda R, Shibutani T, Matsuo T, Kuroiwa T, Shimokawa R, Tajima T. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine. Acta Neuropathol (Berl) 1990;81:66-73.
41. Kuzuhara S, Ohkoshi N, Kanemaru K, Hashimoto H, Nakanishi T, Toyokura Y. Subacute leucoencephalopathy induced by carmofur, a 5-fluorouracil derivative. J Neurol 1987;234:365-70.
42. Vandevelde M, Boring JG, Hoff EJ, Gingerich DA. The effect of levamisole on the canine central nervous system. J Neuropathol Exp Neurol 1978;37:165-73.
43. Bozik ME, Gilbert MR. The role of levamisole in 5-fluorouracil-levamisole-associated multifbcal leukoencephalopathy. Ann Neurol 1994; 36:295. abstract.